Drugs for Hyaline Fibromatosis Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 164)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Dopamine |
Approved |
Phase 4 |
|
51-61-6, 62-31-7 |
681
|
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
2 |
|
Methylphenidate |
Approved, Investigational |
Phase 4 |
|
113-45-1 |
4158
|
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
298-59-9 (hydrochloride)
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
4311/B Ciba
AC1L1HJM
alpha-Phenyl-2-piperidineacetate methyl ester
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
a-Phenyl-2-piperidineacetate methyl ester
a-Phenyl-2-piperidineacetic acid methyl ester
C 4311
C07196
Calocain
Celltech brand OF methylphenidate hydrochloride
Centedein
Centedrin
Centedrine
Centredin
Cephalon brand OF methylphenidate hydrochloride
CHEBI:6887
CHEMBL796
CID4158
Concerta
D04999
Daytrana
Daytrana (TN)
DB00422
DB06701
DEA No. 1724
d-methylphenidate HCl
D-Methylphenidate HCL
EINECS 204-028-6
Equasym
Focalin
Focalin XR
HSDB 3126
Hydrochloride, methylphenidate
L001307
LS-565
Mallinckrodt brand OF methylphenidate hydrochloride
Meridil
Metadate
Metadate CD
Metadate ER
Methyl (2-phenyl-2-(2-piperidyl)acetate)
methyl 2-phenyl-2-piperidin-2-ylacetate
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-(2-piperidyl)acetic acid
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl alpha-phenyl-alpha-2-piperidinylacetic acid
Methyl a-phenyl-a-(2-piperidyl)acetate
Methyl a-phenyl-a-(2-piperidyl)acetic acid
Methyl a-phenyl-a-2-piperidinylacetate
Methyl a-phenyl-a-2-piperidinylacetic acid
Methyl phenidate
|
Methyl phenidyl acetate
Methyl phenidylacetate
Methyl phenidylacetic acid
methyl phenyl(piperidin-2-yl)acetate
methyl α-phenyl-α-(2-piperidyl)acetate
Methyl α-phenyl-α-(2-piperidyl)acetate
Methyl α-phenyl-α-(2-piperidyl)acetic acid
methyl α-phenyl-α-2-piperidinylacetate
Methyl α-phenyl-α-2-piperidinylacetate
Methyl α-phenyl-α-2-piperidinylacetic acid
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
methylphenidate
Methylphenidate
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
Methylphenidate (USAN/INN)
Methylphenidate [INN:BAN]
Methylphenidate HCl
Methylphenidate HCL
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidic acid
Methylphenidylacetate hydrochloride
Methypatch
MethyPatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
MPH
nchembio.2007.55-comp28
NCI-C56280
Novartis brand 1 OF methylphenidate hydrochloride
Novartis brand 2 OF methylphenidate hydrochloride
Phenidylate
Plimasine
PMS-Methylphenidate
Riphenidate
Ritalin
Ritalin hydrochloride
Ritalin LA
Ritalin SR
Ritaline
Ritalin-SR
Ritcher works
Ritcher Works
Tsentedrin
UNII-207ZZ9QZ49
α-phenyl-2-piperidineacetate methyl ester
α-phenyl-2-piperidineacetic acid methyl ester
|
|
3 |
|
Dexmedetomidine |
Approved, Vet_approved |
Phase 4 |
|
113775-47-6 |
68602
5311068
|
Synonyms:
(+)-4-((S)-a,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-α,2,3-trimethylbenzyl)imidazole
113775-47-6
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
AC1NSJXT
C07450
CHEBI:4466
CHEMBL778
CID5311068
D00514
Dexmedetomidin
Dexmedetomidina
Dexmedetomidine
DEXMEDETOMIDINE
Dexmédétomidine
|
Dexmedetomidine (USAN/INN)
Dexmedetomidine hydrochloride
Dexmedetomidinum
Hospira brand OF dexmedetomidine hydrochloride
Hydrochloride, dexmedetomidine
Medetomidina [Spanish]
Medetomidine
Medetomidinum [Latin]
MPV 1440
MPV-1440
NCGC00025347-01
Precedex
PRECEDEX
Precedex (TN)
Tocris-2023
ZINC04632106
|
|
4 |
|
Propofol |
Approved, Investigational, Vet_approved |
Phase 4 |
|
2078-54-8 |
4943
|
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-bis(1-methylethyl)phenol
2,6-bis(1-methylethyl)-phenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-di(propan-2-yl)phenol
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-DIISOPROPYLPHENOL
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
Abbott brand OF propofol
Abbott Brand of Propofol
AC1L1J9Y
AC1Q1OUI
AC-2038
AI3-26295
Alpha Brand of Propofol
Alpha Brand OF propofol
AM-149
Ampofol
Aquafol
Astra brand OF propofol
Astra Brand of Propofol
AstraZeneca brand OF propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
Biomol-NT_000248
BPBio1_000950
BPBio1_000969
Braun brand OF propofol
Braun Brand of Propofol
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD000059151
CPD-11437
Curamed brand OF propofol
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius brand OF propofol
Fresenius Brand of Propofol
Fresenius kabi brand OF propofol
Fresenius Kabi Brand of Propofol
Fresofol
ghl.PD_Mitscher_leg0.558
HMS1570L04
HMS2089O21
HMS2094E17
HSDB 7123
|
ICI 35,868
ICI 35868
ICI35,868
ICI-35,868
ICI35868
ICI-35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste brand OF propofol
Juste Brand of Propofol
Lopac0_000437
Lopac-D126608
LS-996
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
nchembio.552-comp7
NSC 5105
NSC5105
Parnell brand OF propofol
Parnell Brand of Propofol
PFL
Pisa brand OF propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
propofol
Propofol
Propofol (JAN/USAN/INN)
Propofol [USAN:INN:BAN]
Propofol abbott
Propofol Abbott
Propofol fresenius
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol rovi
Propofol Rovi
Propofol(2,6-Diisopropylphenol)
Propofol-lipuro
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi brand OF propofol
Rovi Brand of Propofol
S01-0189
SAM002264610
Schering brand OF propofol
Schering Brand of Propofol
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
Zeneca brand OF propofol
Zeneca Brand of Propofol
ZINC00968303
|
|
5 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4 |
|
137-58-6 |
3676
|
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(diethylamino)-2',6'-Acetoxylidide
2-(Diethylamino)-2',6'-acetoxylidide
2-(diethylamino)-N-(2,6-Dimethylphenyl)acetamide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
a-diethylamino-2,6-Dimethylacetanilide
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
AKOS001026768
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
Alphacaine
alpha-diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-Dimethylacetanilide
alpha-Diethylamino-2,6-dimethylacetanilide
Anestacon
Anestacon Jelly
ARONIS23855
Astrazeneca brand OF lidocaine
BIDD:GT0342
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
C07073
C14H22N2O
Cappicaine
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
Cito optadren
CPD000058189
Cuivasil
D00358
Dalcaine
DB00281
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jenapharm brand OF lidocanine hydrochloride
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L0156
L1026_SIGMA
L7757_SIGMA
Lanabiotic
L-Caine
Leostesin
|
Lida-Mantle
Lidocaina
Lidocaína
Lidocaina [INN-Spanish]
lidocaine
Lidocaine
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine [USAN:INN:JAN]
Lidocaine carbonate
Lidocaine Carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine Hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
Lidocaine Monohydrochloride
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
LIDOPEN
Lignocaine
Lignocainum
Lingocaine
Lopac0_000669
Lopac-L-5647
LQZ
LS-805
Maricaine
Maybridge1_002571
MLS000069724
MLS000758263
MLS001074177
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
nchembio.65-comp16
NINDS_000174
Norwood Sunburn Spray
Novocol brand OF lidocaine hydrochloride
NSC 40030
NSC40030
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
Solarcaine aloe extra burn relief cream
Solcain
SPBio_001525
SPBio_002100
Spectrum_001118
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
STK552033
Strathmann brand OF lidocaine hydrochloride
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
α-diethylamino-2,6-dimethylacetanilide
|
|
6 |
|
Trametinib |
Approved |
Phase 4 |
|
871700-17-3 |
11707110
|
Synonyms:
GSK1120212
JTP-74057
MEK Inhibitor GSK1120212
Mekinist
|
trametinib
Trametinib
Tramétinib
Trametinibum
|
|
7 |
|
Dabrafenib |
Approved, Investigational |
Phase 4 |
|
1195765-45-7 |
44462760
44516822
|
Synonyms:
BRAF inhibitor GSK2118436
dabrafenib
Dabrafenib
|
|
|
8 |
|
Neurotransmitter Uptake Inhibitors |
|
Phase 4 |
|
|
|
9 |
|
Dopamine Uptake Inhibitors |
|
Phase 4 |
|
|
|
10 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
11 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
12 |
|
Peripheral Nervous System Agents |
|
Phase 4 |
|
|
|
13 |
|
Analgesics |
|
Phase 4 |
|
|
|
14 |
|
Central Nervous System Depressants |
|
Phase 4 |
|
|
|
15 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
16 |
|
Glycopyrrolate |
|
Phase 4 |
|
596-51-0 |
3494
|
Synonyms:
(1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate
(1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate bromide
.beta.-1-Methyl-3-pyrrolidyl-.alpha.-cyclopentylmandelate methobromide
1,1-Dimethyl-3-hydroxypyrrolidinium bromide .alpha.-cyclopentylmandelate
1,1-Dimethyl-3-hydroxypyrrolidinium bromide alpha-cyclopentylmandelate
1-Methyl-3-pyrrolidinyl .alpha.-phenylcyclopentaneglycolate methobromide
1-Methyl-3-pyrrolidyl alpha-phenylcyclopentaneglycolate methobromide
3-(erythro-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidiniumbromid
3-Hydroxy-1,1-dimethylpyrrolidinium bromide .alpha.-cyclopentylmandelate
3-Hydroxy-1,1-dimethylpyrrolidinium bromide alpha-cyclopentylmandelate
3-Hydroxy-1,1-dimethylpyrrolidinium bromide-.alpha.-cyclopentylmandelate
53808-86-9
596-51-0
AB00513912
AC-15990
AC1L1G28
AC1L1XX0
AC1LAW54
AC1Q1RGS
AC1Q60WT
AD-237
AHR 504
AHR-504
AR-1J1255
Asecryl
BPBio1_000806
Bromure de glycopyrronium
Bromure de glycopyrronium [INN-French]
Bromure de ritropirronio
Bromure de ritropirronium
Bromuro de glicopirronio
Bromuro de glicopirronio [INN-Spanish]
BSPBio_000732
C19H28NO3
CHEMBL1201027
CHEMBL1201335
CID11693
CID3494
CID521843
Copyrrolate
CPD000469282
Cuvposa
D00540
DB00986
EINECS 209-887-0
Gastrodyn
GLYCOPYRROLATE
Glycopyrrolate (USP)
Glycopyrrolate [USAN]
Glycopyrrolate bromide
Glycopyrroni bromidum
Glycopyrronii bromidum
Glycopyrronii bromidum [INN-Latin]
|
Glycopyrronium
glycopyrronium bromide
Glycopyrronium bromide
Glycopyrronium bromide (JAN/INN)
HMS1570E14
HMS2051P12
HMS2094A05
I14-3643
L001045
LS-138344
Mandelic acid, .alpha.-cyclopentyl-, ester with 3-hydroxy-1,1-dimethylpyrrolidinium bromide
MLS001424112
MLS002222301
MolPort-002-885-831
NCGC00179456-01
Nodapton
NSC 250836
NSC 251251
NSC 251252
NSC250836
NSC251251
NSC251252
NVA 237
NVA-237
Prestwick0_000746
Prestwick1_000746
Prestwick2_000746
Prestwick3_000746
PT-001
Pyrrolidinium, 1,1-dimethyl-3-hydroxy-, bromide, alpha-cyclopentylmandelate
Pyrrolidinium, 3-((cyclopentylhydroxyphenylacetyl)oxy)-1,1-dimethyl-, bromide
Pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-, bromide
Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, .alpha.-cyclopentylmandelate
Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, alpha-cyclopentylmandelate
Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, alpha-cyclopentylmandelate (8CI)
Ritropirronium bromide
Ritropirronium bromide [INN]
Robanul
Robinal
Robinul
Robinul (TN)
ROBINUL FORTE
Salt*)
SAM001246629
SAM002589987
SMR000469282
SPBio_002671
ST51054976
Tarodyl
Tarodyn
UNII-V92SO9WP2I
WLN: T5KTJ A1 A1 COVXQR&- AL5TJ &Q &E
|
|
17 |
|
Adrenergic alpha-2 Receptor Agonists |
|
Phase 4 |
|
|
|
18 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
19 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
20 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
21 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
22 |
|
Anesthetics |
|
Phase 4 |
|
|
|
23 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
24 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
25 |
|
Lamotrigine |
Approved, Investigational |
Phase 2, Phase 3 |
|
84057-84-1 |
3878
|
Synonyms:
3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine
3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
3,5-diamino-6-(2,3-Dichlorophenyl)-1,2,4-triazine
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
3,5-diamino-6-(2,3-Dichlorophenyl)-as-triazine
3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine
84057-84-1
AC-10298
AC1L1GWT
BIDD:GT0794
Bio-0056
BW 430C
BW-430C
C047781
CHEBI:138727
CHEBI:6367
CHEMBL741
CID3878
CPD000058464
Crisomet
D00354
DB00555
Desitin Brand of Lamotrigine
EINECS 281-901-8
EU-0100688
EUR-1048
Faes Brand of Lamotrigine
GI 267119X
Glaxo Wellcome Brand of Lamotrigine
GlaxoSmithKline Brand of Lamotrigine
GW 273293
HMS2051C10
HMS2089M08
HMS2093P21
HSDB 7526
Juste Brand of Lamotrigine
L 3791
L3791_SIGMA
|
Labileno
Lamictal
Lamictal (TN)
Lamictal Cd
Lamictal CD
Lamictal ODT
Lamictal XR
Lamictin
Lamiktal
Lamitor
Lamotrigina
Lamotrigina [Spanish]
lamotrigine
Lamotrigine
Lamotrigine (JAN/USAN/INN)
Lamotrigine [USAN:INN:BAN]
Lamotriginum
Lamotriginum [Latin]
Lopac0_000688
Lopac-L-3791
LS-155249
MLS000069685
MLS000759486
MLS001077325
MolPort-003-666-744
NCGC00015605-01
NCGC00015605-02
NCGC00015605-06
NCGC00015605-08
NCGC00022936-02
NCGC00022936-04
NCGC00022936-05
NSC746307
SAM001246697
SMP2_000303
SMR000058464
STK628377
Tocris-1611
UNII-U3H27498KS
ZINC00013156
|
|
26 |
|
Vincristine |
Approved, Investigational |
Phase 3 |
|
57-22-7, 2068-78-2 |
5978
|
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
Cellcristin
CHEBI:28445
CID5978
Citomid
D08679
DB00541
EINECS 200-318-1
Farmistin
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
LS-228
Marqibo
NCGC00163700-01
NCI60_026703
NCI-C04864
NSC-67574
Onco TCS
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Onkocristin
|
PFS, Vincasar
Sulfate, vincristine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristin bristol
Vincristin medac
Vincristina
Vincristina [DCIT]
vincristine
Vincristine
Vincristine (INN)
Vincristine [INN:BAN]
Vincristine sulfate
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristinum
Vincristinum [INN-Latin]
Vincrisul
Vincrstine
Vincrystine
Vinkristin
Vintec
Z-D-Val-lys(Z)-OH
Z-D-Val-Lys(Z)-OH
|
|
27 |
|
Carboplatin |
Approved |
Phase 3 |
|
41575-94-4 |
10339178
498142
38904
|
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
azanide
Blastocarb
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
Carbopaltin
Carboplat
carboplatin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Carbosin
Carbotec
Cbdca
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylic acid
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
|
DivK1c_000892
EINECS 255-446-0
Ercar
EU-0100230
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
IUPAC: Azane
JM 8
JM8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac0_000230
Lopac-C-2538
LS-117689
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
Nealorin
Neocarbo
NINDS_000892
NSC 201345
NSC 241240
NSC201345
NSC241240
NSC-241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
platinum(2+)
Platinum(II), (1, 1-cyclobutanedicar
Platinum, {diammine[1,1-cyclobut
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Ribocarbo
S1215_Selleck
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
UNII-BG3F62OND5
|
|
28 |
|
Calcium |
Approved, Nutraceutical |
Phase 2, Phase 3 |
|
7440-70-2 |
271
|
Synonyms:
Blood coagulation factor XIII
Ca
Ca(2+)
Ca2+
Calcio
Calcium
Calcium element
CALCIUM ion
Calcium, doubly charged positive ion
Calcium, elemental
Coagulation factor XIII
Elemental calcium
Factor XIII
|
Factor XIII a chain
Factor XIII a-chain
Factor XIII transamidase
Factor XIII, coagulation
Fibrin stabilizing factor
Fibrinase
Kalzium
Laki lorand factor
Laki-lorand factor
Stabilizing factor, fibrin
Transamidase, factor XIII
XIII, coagulation factor
|
|
29 |
|
Hormones |
|
Phase 2, Phase 3 |
|
|
|
30 |
|
Tranquilizing Agents |
|
Phase 2, Phase 3 |
|
|
|
31 |
|
Chlorhexidine gluconate |
|
Phase 2, Phase 3 |
|
|
|
32 |
|
Diuretics, Potassium Sparing |
|
Phase 2, Phase 3 |
|
|
|
33 |
|
Sodium Channel Blockers |
|
Phase 2, Phase 3 |
|
|
|
34 |
|
Antipsychotic Agents |
|
Phase 2, Phase 3 |
|
|
|
35 |
|
Psychotropic Drugs |
|
Phase 2, Phase 3 |
|
|
|
36 |
|
Anticonvulsants |
|
Phase 2, Phase 3 |
|
|
|
37 |
|
calcium channel blockers |
|
Phase 2, Phase 3 |
|
|
|
38 |
|
Calcium, Dietary |
|
Phase 2, Phase 3 |
|
|
|
39 |
|
Antineoplastic Agents, Phytogenic |
|
Phase 3 |
|
|
|
40 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
41 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
42 |
|
Celecoxib |
Approved, Investigational |
Phase 2 |
|
169590-42-5 |
2662
|
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC1L1E6K
AC-4228
AI-525
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
celecoxib
Celecoxib
Célécoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
cMAP_000027
CPD000550473
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
|
KBio2_000912
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
Medicoxib
MLS001165684
MLS001195656
MLS001304708
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC58635
SC-58635
SMR000550473
Solexa
SPBio_001512
Spectrum_000432
SPECTRUM1503678
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM177
YM-177
ZINC02570895
|
|
43 |
|
Temozolomide |
Approved, Investigational |
Phase 2 |
|
85622-93-1 |
5394
|
Synonyms:
3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide
3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
85622-93-1
8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
AC1L1K9B
AC-758
BIDD:GT0204
Bio-0147
BRN 5547136
C047246
C6H6N6O2
CCRG 81045
CCRG-81045
CCRIS 8996
CHEBI:153686
CHEMBL810
CID5394
CPD000466338
D06067
DB00853
Essex brand of temozolomide
HMS2051O12
HMS2090B08
I06-0149
I14-1943
LS-80558
M B 39831
m & b 39831
M & B 39831
m And b 39831
m And b-39831
|
M&B 39831
M&B-39831
M-39831
MB 39831
Methazolastone
MLS000759447
MLS001424028
MLS002701861
NCGC00167429-01
NCGC00167429-02
NCI60_003316
NSC 362856
NSC362856
NSC-362856
SAM001246636
Sch 52365
SCH 52365
Sch-52365
Schering brand of temozolomide
Schering-Plough brand of temozolomide
SMR000466338
STK623541
Temodal
Temodal (TN)
Temodar
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
temozolomide
Temozolomide
Témozolomide
Temozolomide (JAN/USAN/INN)
Temozolomide [INN:BAN]
Temozolomidum
Temozolomidum [Latin]
TL8005593
TMZ
TMZ-Bioshuttle
UNII-YF1K15M17Y
ZINC01482184
|
|
44 |
|
Peginterferon alfa-2b |
Approved |
Phase 2 |
|
99210-65-8, 215647-85-1 |
|
Synonyms:
215647-85-1
D02748
Peginterferon alfa-2b
Peginterferon alfa-2b (generical recombination)
Peginterferon alfa-2b (generical recombination) (JAN)
|
Peginterferon alfa-2b (INN)
PegIntron
PEG-Intron
Pegintron (TN)
Unitron PEG
|
|
45 |
|
Pirfenidone |
Approved, Investigational |
Phase 2 |
|
53179-13-8 |
40632
|
Synonyms:
5-21-07-00197 (Beilstein Handbook Reference)
53179-13-8
5-Methyl-1-phenyl-1H-pyridin-2-one
5-Methyl-1-phenyl-2(1H)-pyridone
5-Methyl-1-phenyl-2-(1H)-pyridone
5-methyl-1-phenylpyridin-2(1H)-one
5-methyl-1-phenylpyridin-2-one
AC1L2454
AC-6797
AMR 69
AMR-69
Bio1_000397
Bio1_000886
Bio1_001375
BRD-K96862998-001-03-1
BRN 1526549
C093844
C12H11NO
CID40632
D01583
Deskar
EN000704
Esbriet
EU-0100907
F-647
FT-0082541
I01-1466
KS-5041
|
Lopac0_000907
Lopac-P-2116
LS-133834
MLS000860042
NCGC00015806-01
NCGC00015806-03
NCGC00015806-05
NCGC00024992-01
NCGC00024992-02
NCGC00024992-03
P 2116
P2116_SIGMA
Pirespa
pirfenidona
Pirfenidona
Pirfenidona [INN-Spanish]
Pirfenidone
PIRFENIDONE
Pirfenidone (Deskar)
Pirfenidone (JAN/USAN/INN)
Pirfenidone [USAN:INN]
Pirfenidonum
Pirfenidonum [INN-Latin]
S-7701
SMR000326900
Tocris-1093
ZINC00001958
|
|
46 |
|
Methotrexate |
Approved |
Phase 2 |
|
1959-05-2, 59-05-2 |
126941
|
Synonyms:
4-amino-10-Methylfolate
4-amino-10-methylfolic acid
4-amino-10-Methylfolic acid
4-amino-N(10)-Methylpteroylglutamate
4-amino-N(10)-methylpteroylglutamic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Dicesium salt methotrexate
Emtexate
Emtexic acid
Folex
HDMTX
Hydrate, methotrexate
L-Amethopterin
Ledertrexate
Ledertrexic acid
Metatrexan
Methopterin
Methotextrate
Methotrate
Methotrexat
|
Methotrexate
Méthotrexate
Methotrexate hydrate
Methotrexate sodium
Methotrexate Sodium
Methotrexate, (D)-isomer
Methotrexate, (DL)-isomer
Methotrexate, dicesium salt
Methotrexate, disodium salt
Methotrexate, sodium salt
Methotrexatum
Methotrexic acid
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
MTX
N-[4-[[(2,4-diamino-6-Pteridinyl)methyl]methylamino]benzoyl]-L-glutamate
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-[4-[[(2,4-diamino-6-Pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-Bismethylpteroylglutamic acid
N-Bismethylpteroylglutamic Acid
Rheumatrex
Sodium, methotrexate
Trexall
|
|
47 |
|
Vinblastine |
Approved |
Phase 2 |
|
865-21-4 |
241903
13342
|
Synonyms:
(2a,2'b,3b,4a,5b)-VINCALEUKOBLASTINE
(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE
(2xi,3beta,4'beta,19xi)-vincaleukoblastine
(2α,2'β,3β,4α,5β)-vincaleukoblastine
(3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate
143-67-9
1z2b
29060-LE
865-21-4
AC1L21JC
AC1L68D2
AC1MXZJ2
AC-20335
BIDD:PXR0201
Bio-0111
BRD-K01188359-065-02-5
BSPBio_001228
BSPBio_003594
C07201
C46H58N4O9
CCRIS 9002
Cell pharm brand OF vinblastine sulfate
Cellblastin
CHEBI:171516
CHEBI:27375
CHEMBL159
CHEMBL607706
CID13342
CID241903
CID3823887
CID6710780
D08675
DB00570
EG labo brand OF vinblastine sulfate
EINECS 212-734-0
Faulding brand OF vinblastine sulfate
Gastrozepin brand OF vinblastine sulfate
Gry brand OF vinblastine sulfate
Hexal brand OF vinblastine sulfate
HMS2090K05
HSDB 3263
KBio3_003033
Lemblastine
Lemery brand OF vinblastine sulfate
Lilly brand OF vinblastine sulfate
|
LS-1859
LS-187263
MolPort-002-518-262
MolPort-005-910-359
NCGC00022585-04
NCGC00181127-01
NChemBio.2007.10-comp22
nchembio873-comp22
NCI60_004200
NCI-C04842
NDC 0002-1452-01
Neuro_000020
Nincaluicolflastine
NSC 47842
Rozevin
SPBio_000680
Spectrum2_000890
Spectrum3_001994
STOCK1N-38480
Sulfate, vinblastine
UNII-5V9KLZ54CY
Velban
Velbe
Vinblastin
Vinblastin hexal
Vinblastina
Vinblastina (TN)
Vinblastina [Dcit]
Vinblastina [DCIT]
Vinblastina lilly
vinblastine
Vinblastine
Vinblastine (INN)
Vinblastine [INN:BAN]
Vinblastine sulfate
Vinblastine Sulfate
Vinblastinsulfat-gry
Vinblastinum
Vinblastinum [INN-Latin]
Vincaleucoblastin
Vincaleucoblastine
Vincaleukoblastine
Vincoblastine
VLB
VR-8
|
|
48 |
|
leucovorin |
Approved |
Phase 2 |
|
58-05-9 |
143
6006
|
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-formyltetrahydrofolate
5-Formyltetrahydrofolate
5-formyltetrahydrofolic acid
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
Acid, folinic
Acide folinique
Acido folinico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
Citrovorum factor
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
|
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monosodium salt
Leucovorinum
Leukovorin
Leukovorum
Levoleucovorin
L-leucovorin
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Rescuvolin
Welcovorin
Wellcovorin
|
|
49 |
|
Diclofenac |
Approved, Vet_approved |
Phase 2 |
|
15307-86-5 |
3033
|
Synonyms:
(2,6-Dichlorophenyl)amino]benzeneacetic acid
[2-(2,6-dichloroanilino)Phenyl]acetate
[2-(2,6-dichloroanilino)phenyl]acetic acid
[2-(2,6-dichloroanilino)Phenyl]acetic acid
[o-(2,6-Dichloroanilino)phenyl]acetic acid
{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid
15307-81-0 (mono-potassium salt)
15307-86-5
2-((2,6-Dichlorophenyl)amino)benzeneacetate
2-((2,6-dichlorophenyl)amino)benzeneacetic acid
2-((2,6-Dichlorophenyl)amino)benzeneacetic acid
2-(2,6-Dichloroanilino)phenylacetic Acid
2-(2,6-Dichlorophenylamino)phenylacetic acid
2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid
2-[2-(2,6-dichloroanilino)phenyl]acetic acid
2-[2-(2,6-Dichlorophenylamino)phenyl]acetic acid
2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID
2b17
AC1L1F0T
Acetic acid, [o-(2,6-dichloroanilino)phenyl]- (8CI)
AKOS001579542
Allvoran
Apo-Diclo
Assaren
Benfofen
Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)- (9CI)
BIDD:GT0380
BPBio1_000516
BRD-K08252256-236-05-6
BRN 2146636
BSPBio_000468
BSPBio_002169
C01690
Cataflam
CHEBI:47381
CHEMBL139
CID3033
cMAP_000014
D07816
D30801
D3748
DB00586
Delphimix
dichlofenac
Dichlofenac
Dichlofenal
Dichronic
Diclac
Diclobenin
diclofenac
Diclofenac
Diclofenac (INN)
Diclofenac [INN:BAN]
Diclofenac acid
Diclofenac Acid
Diclofenac potassium
Diclofenac Potassium
Diclofenac sodium
Diclofenac Sodium
Diclofenac, sodium
Diclofenaco
Diclofenaco [INN-Spanish]
Diclofenacum
Diclofenacum [INN-Latin]
Diclofenamic acid
Diclomelan
Diclonate P
Diclophenac
Diclo-Phlogont
Diclo-Puren
Diclord
Dicloreum
Dicloreuma
Dicrofenac
DIF
DivK1c_000272
DivK1c_000402
Dolobasan
Duravolten
Dyloject
Ecofenac
Effekton
|
EINECS 239-348-5
Feloran
GP-45,840
henyl)-o-aminophenylacetic acid
HMS2090C10
HMS501E04
HSDB 7234
I14-7739
IDI1_000272
IDI1_000402
ISV-205
KBio1_000272
KBio1_000402
KBio2_001410
KBio2_002306
KBio2_003978
KBio2_004874
KBio2_006546
KBio2_007442
KBio3_001389
KBio3_002786
KBioGR_001051
KBioGR_002306
KBioSS_001410
KBioSS_002308
Kriplex
Lopac0_000441
LS-11575
MolPort-000-003-072
N-(2,6-Dichlorop
NCGC00021125-01
Neriodin
NINDS_000272
NINDS_000402
Novapirina
Novo-Difenac
Novo-Difenac SR
Nu-Diclo
Oprea1_011155
Orthofen
Orthophen
Ortofen
Pennsaid
Prestwick0_000594
Prestwick1_000594
Prestwick2_000594
Prestwick3_000594
Primofenac
Prophenatin
ProSorb-D
Rhumalgan
SBB068617
Sodium diclofenac
Solaraze
Solaraze (TN)
Solaraze T
SPBio_001081
SPBio_002687
Spectrum_000930
Spectrum2_000991
Spectrum3_000385
Spectrum4_000506
Spectrum5_000867
SR 38
SR-38
STK984493
Transfenac
Tsudohmin
UNII-144O8QL0L1
UNM000001216103
Valetan
Voldal
Voltaflan
Voltaren
Voltaren Ophtha
Voltaren ophthalmic
Voltaren Ophthalmic
Voltaren Rapide
Voltaren SR
Voltaren-XR
Voltarol
Xenid
|
|
50 |
|
Lapatinib |
Approved, Investigational |
Phase 2 |
|
388082-78-8, 231277-92-2 |
208908
9941095
|
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW2016
GW-2016
GW572016
GW-572016
GW-572016F
HMS2089H10
I01-1247
Kinome_3684
Kinome_3685
lapatinib
|
Lapatinib
Lapatinib (INN)
Lapatinib [INN]
lapatinib ditosylate
Lapatinib ditosylate
Lapatinib Ditosylate
Lapatinib ditosylate (USAN)
LAPATINIB DITOSYLATE MONOHYDRATE
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
LS-187029
LS-187771
N-(3-chloro-4-(((3-Fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine
N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulphonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
NCGC00167507-01
nchembio866-comp20
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
|
|
Interventional clinical trials:
(show top 50)
(show all 150)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Comportemental and Neuropsychologic Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate. A Double-blind Randomised Study Methylphenidate Versus Placebo |
Completed |
NCT00169611
|
Phase 4 |
methylphenidate |
2 |
An Observer-blinded Randomized Study of Propofol Infusion vs Bolus Dexmedetomidine and Propofol Sedation for Pediatric Magnetic Resonance Imaging |
Recruiting |
NCT03513757
|
Phase 4 |
propofol;Dexmedetomidine |
3 |
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) |
Not yet recruiting |
NCT03975829
|
Phase 4 |
dabrafenib;trametinib |
4 |
The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial (NF1-EXCEL) |
Recruiting |
NCT02256124
|
Phase 2, Phase 3 |
Lamotrigine;Placebo |
5 |
Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain: A Phase III Clinical Trial |
Recruiting |
NCT02471339
|
Phase 3 |
|
6 |
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) |
Not yet recruiting |
NCT03871257
|
Phase 3 |
Carboplatin;Selumetinib;Selumetinib Sulfate;Vincristine;Vincristine Sulfate |
7 |
Medical Treatment of "High-Risk" Neurofibromas in Patients With Type 1 Neurofibromatosis: A Clinical Trial of Sequential Medical Therapies |
Unknown status |
NCT00846430
|
Phase 2 |
Peg-Interferon alpha-2b;Celecoxib (Celebrex);Temozolomide (temodar);Vincristine Sulfate (Oncovin) |
8 |
Icotinib Hydrochloride Tablets Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors |
Unknown status |
NCT02934256
|
Phase 2 |
Icotinib |
9 |
Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1- CRAD001CUS232T |
Completed |
NCT02332902
|
Phase 2 |
Everolimus |
10 |
Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 |
Completed |
NCT00004437
|
Phase 2 |
|
11 |
Phase II Clinical Trial of Pirfenidone for the Treatment of Patients With Neurofibromatosis Type I |
Completed |
NCT00754780
|
Phase 2 |
Pirfenidone |
12 |
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas |
Completed |
NCT01673009
|
Phase 2 |
Gleevec |
13 |
A Single Arm, Multicenter Phase II a Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas That Cannot be Removed by Surgery |
Completed |
NCT01412892
|
Phase 2 |
RAD001: Everolimus |
14 |
Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping |
Completed |
NCT02104323
|
Phase 2 |
Endostatin |
15 |
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma |
Completed |
NCT00589784
|
Phase 2 |
Sunitinib |
16 |
Vinblastine/Methotrexate For Severe Progressive Plexiform Neurofibromas: A Phase II Study |
Completed |
NCT00030264
|
Phase 2 |
Methotrexate;Vinblastine |
17 |
A Single Arm, Single Center, Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma |
Completed |
NCT01490476
|
Phase 2 |
RAD001 |
18 |
Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas |
Completed |
NCT01140360
|
Phase 1, Phase 2 |
Gleevec |
19 |
Clinical Assessment of the Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With Neurofibromatosis Type 1 |
Completed |
NCT03090971
|
Phase 2 |
Diclofenac Sodium;Saline Solution |
20 |
Phase II Trial of Pirfenidone in Children, Adolescents, and Young Adults With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas |
Completed |
NCT00076102
|
Phase 2 |
Pirfenidone |
21 |
Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma |
Completed |
NCT01207687
|
Phase 2 |
|
22 |
Phase II Study of Lapatinib in Children and Adults With Neurofibromatosis Type 2(NF2) and NF2-related Tumors |
Completed |
NCT00973739
|
Phase 2 |
Lapatinib |
23 |
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 |
Completed |
NCT00853580
|
Phase 2 |
Lovastatin â„¢ |
24 |
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas |
Completed |
NCT00634270
|
Phase 2 |
Sirolimus |
25 |
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 |
Completed |
NCT01419639
|
Phase 2 |
Everolimus (RAD001) , Afinitor® |
26 |
Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors |
Completed |
NCT00304083
|
Phase 2 |
doxorubicin hydrochloride;etoposide;ifosfamide |
27 |
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas |
Completed |
NCT02096471
|
Phase 2 |
PD-0325901 |
28 |
Phase 2 Study of Imatinib in Children With Neurofibromatosis and Airway Tumors |
Recruiting |
NCT03688568
|
Phase 2 |
Imatinib Mesylate |
29 |
Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas |
Recruiting |
NCT03079999
|
Phase 2 |
Aspirin;Placebo |
30 |
Treatment of NF1-related Plexiform Neurofibroma With Trametinib; a Single Arm, Open-label Trial With the Goals of Volumetric Partial Remission and Pain Relief |
Recruiting |
NCT03741101
|
Phase 2 |
Trametinib |
31 |
Topical Photodynamic Therapy (PDT) With Levulan® Kerastick® for Benign Dermal Neurofibromas Phase II |
Recruiting |
NCT02728388
|
Phase 2 |
|
32 |
Phase II Trial to Evaluate Trametinib in Patients With Advanced NF1-mutant Non-small Cell Lung Cancer |
Recruiting |
NCT03232892
|
Phase 2 |
Trametinib |
33 |
Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF) |
Recruiting |
NCT02839720
|
Phase 2 |
Selumetinib |
34 |
Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors |
Recruiting |
NCT03095248
|
Phase 2 |
Selumetinib |
35 |
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia |
Recruiting |
NCT03190915
|
Phase 2 |
Trametinib |
36 |
SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors |
Recruiting |
NCT03433183
|
Phase 2 |
Selumetinib;Sirolimus |
37 |
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas |
Recruiting |
NCT02407405
|
Phase 2 |
Selumetinib |
38 |
Neurobiology and Treatment of Reading Disability in NF1 |
Recruiting |
NCT02964884
|
Phase 2 |
Lovastatin;Placebo Oral Tablet |
39 |
A Phase II Trial on the Effect of Low-Dose Versus High-Dose Vitamin D Supplementation on Bone Mass in Adults With Neurofibromatosis Type 1 (NF1) |
Recruiting |
NCT01968590
|
Phase 2 |
Cholecalciferol |
40 |
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010) |
Recruiting |
NCT03231306
|
Phase 2 |
Binimetinib |
41 |
A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma |
Recruiting |
NCT01089101
|
Phase 1, Phase 2 |
Selumetinib |
42 |
Phase I/II Trial of PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) |
Recruiting |
NCT02390752
|
Phase 1, Phase 2 |
PLX3397 |
43 |
A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults |
Recruiting |
NCT02101736
|
Phase 2 |
Cabozantinib |
44 |
A Study of INFUSE Bone Graft (Recombinant Human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis 1 (NF1) |
Active, not recruiting |
NCT02718131
|
Phase 2 |
|
45 |
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas |
Active, not recruiting |
NCT01125046
|
Phase 2 |
|
46 |
A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma |
Active, not recruiting |
NCT01345136
|
Phase 2 |
RAD001, everolimus |
47 |
A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas |
Active, not recruiting |
NCT02831257
|
Phase 2 |
AZD2014 |
48 |
A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; HYD Sulfate) in Children With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) |
Active, not recruiting |
NCT01362803
|
Phase 1, Phase 2 |
AZD6244 |
49 |
Phase II Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas |
Active, not recruiting |
NCT02129647
|
Phase 2 |
Axitinib |
50 |
Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation |
Active, not recruiting |
NCT01767792
|
Phase 2 |
Bevacizumab |
|